A 44-year-old patient who had had acute monoblastic leukemia developed an osteosarcoma of the pelvic bones 5 years after an allogeneic bone marrow transplant from his HLA-identical sister. He had additionally received superficial cutaneous radiation of the legs and pelvis, over the 3 weeks prior to total body irradiation (TBI), because of cutaneous leukemic lesions. The tumor was a fibrohistiocytomatous osteogenic sarcoma. The first lesion was in the right ilium, and a second lesion appeared 18 months later, symmetrically on the left ilium. Despite treatment, the patient died from metastases. At the time of diagnosis of radiation-induced sarcoma, the patient was free of leukemia and had several risk factors already reported to favor the development of solid tumors in stem cell recipients. These include acute leukemia, TBI and graft-versus-host disease. As he developed symmetrical lesions of the pelvic bone, and because of the histology of the radiationinduced tumor, we assumed that the additional radiation of the skin prior to TBI may have contributed to the pathogenesis of this malignant fibrous histiocytoma. Therefore, the risk/benefit ratio should be carefully considered in unusual indications. These patients should benefit from a close follow-up of the superimposed areas. Bone Marrow Transplantation (2000) 25, 1011-1013. Keywords: radiation-induced sarcoma; total body irradiation; secondary malignancy; stem cell transplantation Due to the success of stem cell transplantation and to the increasing life expectancy of these patients, more is known about the late complications of the procedure. It is now clear that stem cell transplant predisposes to an increased risk of new solid cancers when compared to the expected cases in the general population. predisposition to chromosome fragility as in Fanconi anemia, prolonged immunosuppressive therapy, viruses such as Epstein-Barr virus, and radiation. The role of each of these factors is difficult to determine, since they almost always overlap in this population, especially in allogeneic stem cell transplant recipients. As for radiation, total body irradiation (TBI) is widely used in the conditioning regimen of stem cell transplantation; 2 additional radiation, before or after TBI, is more unusual. Sarcomas are a rare complication of radiation therapy and have been occasionally reported after radiation for breast cancer, gynecological cancer, Hodgkin's disease, and other types of cancer.
predisposition to chromosome fragility as in Fanconi anemia, prolonged immunosuppressive therapy, viruses such as Epstein-Barr virus, and radiation. The role of each of these factors is difficult to determine, since they almost always overlap in this population, especially in allogeneic stem cell transplant recipients. As for radiation, total body irradiation (TBI) is widely used in the conditioning regimen of stem cell transplantation; 2 additional radiation, before or after TBI, is more unusual. Sarcomas are a rare complication of radiation therapy and have been occasionally reported after radiation for breast cancer, gynecological cancer, Hodgkin's disease, and other types of cancer. 5 In 1948, Cahan et al 6 defined the criteria for the diagnosis of radiation-induced sarcoma: (1) prior history of radiation treatment; (2) asymptomatic latent period of several years; (3) occurrence of a sarcoma within a previously irradiated field; and (4) histological confirmation of sarcomatous nature of the post-irradiation lesion.
In this paper, we report a case of radiation-induced sarcoma occurring after TBI in an allogeneic stem cell recipient, and because of the histological characteristics and the localization of the tumors, we discuss the additional risk of prior cutaneous irradiation combined with TBI.
Case report
A 44-year-old patient was referred to our Hematology Department with acute monoblastic leukemia in June 1989. He achieved complete remission (CR) after an induction regimen including arabinosyl-cytosine, doxorubicin, and CCNU, and then was given 3 months of maintenance therapy. He received CNS radiation (ϫ4 MV; 18 Gy/10 fractions, 2 weeks) as prophylaxis for meningeal disease during the second month of remission. Extra-medullary relapse was diagnosed 3 months after achieving CR on the occurrence of cutaneous lesions on the legs and pelvis, and histologically proven to be monoblastic infiltrates. He was given a new chemotherapy (high-dose arabinosyl-cytosine for 5 days and amsacytidine for 3 days) with significant, but incomplete decrease of the lesions. Then, he underwent superficial radiation therapy (45 kV; 30 Gy/12 fractions; 3 weeks) to the skin of the legs and pelvis, 3 weeks prior to a geno-identical stem cell transplant from his sister in October 1989. The conditioning regimen included mel- phalan, CCNU, VP16, and 10 Gy TBI in one fraction using a cobalt unit. Prophylaxis of graft-versus-host disease (GVHD) included cyclosporine and a short course of methotrexate. The patient experienced no acute GVHD, and limited chronic GVHD with oral lichen lesions and abnormal liver function tests and received azathioprine for 6 months. In December 1995, the occurrence of pelvic pain led to a diagnosis of locally advanced osteosarcoma of the right ilium (14 ϫ 10 cm) with involvement of the soft tissue. Microscopically the bone tumor was characterized by atypical spindle cells, proliferation with focal storiform pattern, heavily collagenized area, moderate necrosis and inflammatory cell infiltration ( Figure 1 ). No tumoral osteogenesis was observed. Nevertheless, high tumor cell alkaline phosphatase positivity was demonstrated in cytological smears ( Figure 2 ). Diagnosis of poorly differentiated malignant fibrohistiocytoma-like osteosarcoma was made. P53 reactivity was demonstrated by immunohistochemistry in 30% of the tumor cells. The tumor was retrospectively shown to be of recipient origin, using FISH for chromosome Y. There was no sign of relapse of the leukemia, either on biopsies, or on marrow aspirations. No metastatic lesion was found by CT scan. The tumor was surgically removed and the soft tissue sections showed positive margins with infiltration of the muscle. The patient received a combination of ifosfamide, thiotepa, and adriamycin as adjuvant treatment. Micronodular lesions consistent with lung metastases appeared while on treatment. A treatment with high-dose methotrexate was performed followed by palliative irradiation of right pelvic bone with a total dose of 30 Gy in 10 fractions. In September 1996, a new bone lesion appeared on the left iliac crest, symmetrical with respect to the initial tumor of the right iliac crest. The tumor was 12 ϫ 7 cm with destruction of ilium with soft tissue extension and indefinite infiltrative borders. Post-radiation necrosis was seen in the non-tumoral bone area (Figure 3 ). This tumor was resected after a poor response following neoadjuvant chemotherapy with two poorly tolerated courses of high-dose methotrexate. The patient died in January 1997 from locally advanced disease and lung metastases, in CR of his leukemia.
Discussion
Since the animal models of the 1970s have already shown the increased susceptibility of bone marrow recipients to malignancies, 3, 4 this late side-effect could also be expected in humans. Several large series have reviewed the incidence of neoplasia after stem cell transplant and all have confirmed this increased risk. In the series of 2150 stem cell transplant recipients of Bhatia et al, 1 the incidence has been estimated to be 9.9 Ϯ 2.3% for any post-SCT malignancy, and 5.6 Ϯ 2.2% for solid tumors after 13 years. In the series of Curtis et al 2 studying 19 229 recipients from allo-or syngeneic transplantation, the risk of solid cancers was estimated to be 8.3 times higher than expected in the general population among 10 year survivors. Several risk factors have been identified for the occurrence of this complication, varying according to the series. These variations in incidence may be explained by the overall analysis of different kinds of tumors, or differences in the populations. However, several risk factors are common to most of the larger series, especially radiation, male gender, acute leukemia rather than aplastic anemia or lymphoma, chronic GVH disease, and treatment of chronic GVHD with azathioprine. 1, 2 As for TBI, single dose, rather than fractionated TBI, and higher cumulative radiation doses were associated with an increased risk of solid tumor. 2 Among these malignancies, bone tumors appear to be extremely rare, since only five cases (three between 1 and 4 years post transplant, and two later) were reported among the 19 229 patients of the series of Curtis, and only one was reported among the 2150 recipients of bone marrow transplant in the series of Bhatia.
1,2 As this event is extremely rare, it is difficult to identify particular risk factors for bone tumors, and especially the role of additional radiation prior to or after TBI. However, additional radiation is probably not insignificant as the large reviews show that CNS radiation was associated with an increased risk of brain tumor. 7 The role of radiation in the occurrence of bone sarcoma is well known in other settings, even if it is also of rare occurrence. Several events such as Hiroshima and Nagasaki have provided information about this subject. 8 Taghian et al 9 reported that the cumulative incidence of radiationinduced sarcomas among 6919 patients irradiated after breast cancer was 0.2% at 10 years, 0.43% at 20 years and 0.78% at 30 years. Mark et al 10 reported 37 cases of radiation induced sarcoma among 1089 patients and a risk of 0.03-0.8%. The most commonly reported dose for radiation induced sarcoma is 60-80 Gy 5, 8, 10 with a recognized minimal dose of 10 Gy in conventional fractionation. Radiationinduced sarcomas are associated with poor prognosis because most of them are diagnosed in advanced stage 5, 10 and frequently located in areas where radical surgery is impossible. However, radical surgery probably offers the best chance of cure to the patient. 5 The response to chemotherapy is poor, leading to only partial and short remissions. 5 Our patient had several known risk factors for developing a secondary cancer: he was male, had acute leukemia, was 44 years old at transplant, and had a donor who was more than 30 years old. Moreover, he received nonfractionated TBI, developed chronic GVHD and was treated with azathioprine. He survived more than 4 years after the graft, which is the minimal latency time reported for the occurrence of a radiation induced sarcoma after conventional radiation. As megavoltage, inherent to TBI, has been associated with a shorter latency period, 5, 8, 10 it can be expected that radiation-induced sarcoma occurs earlier after TBI than after nonTBI radiation.
As there is usually no preferential localization of radiation induced sarcoma to the pelvis, the symmetrical lesions were in the radiation field, and as the tumor had characteristics of radiation-induced tumor, we assume that the evolution of this case was the consequence of the additional Bone Marrow Transplantation radiation the patient received before TBI. Although he received a superficial cutaneous radiation which was not intended to irradiate the bones, the thin body of the patient may have favored the delivery of radiation to the external part of the bone.
As the prognosis of radiation induced sarcoma is extremely severe, such patients who have received additional radiation to TBI should benefit from close follow-up, with sequential radiologic and tomodensitometric evaluations, in order to make an early diagnosis at a stage where the surgical removal of the tumor could potentially result in cure.
